Stockreport

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential [Yahoo! F...

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Excluding Japan BV, revenues increased 5% YoY in LC. Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 b [Read more]